Filing Flows › Comparisons › HUMA vs RLAY
Humacyte vs Relay Therapeutics: HUMA and RLAY compared
Humacyte is the larger company: $406K of revenue in its latest quarter (Q2 2026) against $350K for Relay Therapeutics (Q2 2026). Humacyte is growing faster (+35% against -48% a year earlier).
Where the money goes: HUMA and RLAY
Humacyte (HUMA) · Q2 2026
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Relay Therapeutics (RLAY) · Q2 2026
Relay Therapeutics, Q2 2026: revenue $350K (-48% year over year), net loss $83.7M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
| Humacyte (HUMA) | Relay Therapeutics (RLAY) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $406K | $350K |
| Revenue growth, Y/Y | +35% | -48% |
| Operating margin | n/m | n/m |
| Net earnings | −$36.8M | −$83.7M |
| Operating cash flow | −$22.1M | −$54.1M |
Questions
Which is bigger, Humacyte or Relay Therapeutics?
Humacyte is the larger company: $406K of revenue in its latest quarter (Q2 2026) against $350K for Relay Therapeutics (Q2 2026).
Is Humacyte or Relay Therapeutics growing faster?
Humacyte is growing faster (+35% against -48% a year earlier).
More: Humacyte earnings · how Humacyte makes money · Relay Therapeutics earnings · how Relay Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.